

January, 2025
Wyndham H. Wilson

CURRICULUM VITAE

Name: Wyndham Hopkins Wilson

Citizenship: United States

Place of Birth: San Francisco, California

Work Address: National Cancer Institute
9000 Rockville Pike
Bethesda, Maryland 20892

Current Position: Chief, Lymphoma Therapeutics Section
Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute

Education

1970-1974 B.A. (Human Biology)
Stanford University, Stanford, CA

1974-1975 M.S. (Biology)
Stanford University, Stanford, CA

1975-1981 Ph.D. (Neurobiology)
Stanford University, Stanford, CA

M.D. (Stanford School of Medicine)
Stanford University, Stanford, CA

Positions

1976-1977	Teaching Assistant, Department of Neurobiology, Stanford University, Stanford, CA
1978	Acting Assistant Instructor, Department of Neurobiology, Stanford University, Stanford, CA
1979-1980	Teaching Assistant, Department of Neurobiology, Stanford University, Stanford, CA
1981-1982	Internship, Department of Medicine, Stanford University, Stanford, CA
1982-1984	Junior and Senior Resident, Department of Medicine, Stanford University, Stanford, CA
1984-1987	Medical Staff Fellow, Medicine Branch, National Cancer Institute, NIH, Bethesda, MD
1985-1994	Emergency Department Physician, City Hospital, Martinsburg, West Virginia (Part-time).
1987-1988	Medical Staff Fellow, Pediatric Branch, Infectious Disease Section, National Cancer Institute, NIH, Bethesda, MD
1988-1995	Special Assistant to the Director, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, MD
1995-2002	Senior Investigator, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD
1997-2008	Chief, Lymphoma Clinic, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD
1997-1998	Oncology Fellowship Coordinator, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD
1998-1999	Chief, Clinical Core, Metabolism Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD
2002-2005	Senior Investigator, Chief, Lymphoma Section, Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, MD.

2005-Present Senior Investigator, Chief, Lymphoid Malignancies Therapeutic Section, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Licensed to Practice Medicine

California Certificate No. G49178

Certification

1982 Diplomat, National Board of Medical Examiners
1985 Diplomat, American Board of Internal Medicine
1987 Diplomat, Subspecialty of Oncology, American Board of Internal Medicine

Committees at NIH

1988-1989 Chairman, Fluoro-dideoxyinosine and Fluoro-dideoxycytidine Licensing Committee, DCT, NCI
1988-1995 Chairman, Animal Care and Use Committee, DCT, NCI
1992-1993 Member, Natural Products Repository Review Committee
1992-1995 Member, Institutional Review Board, NCI
1995-2008 Member, Protocol Review and Monitoring Committee, DCS, NCI
1995-2002 Chairman, Institutional Review Board, NCI
1999-2001 Member, Promotions and Tenure Review Committee, DCS, NCI
2001-2007 Chairman, Promotions and Tenure Review Committee for Clinical Staff, CCR, NCI

Academic Honors

1974	B.A. with Honors in Human Biology
1976-1981	Medical Scientist Training Program Grant Award
1994	Merit Award, National Institutes of Health
1997	Teacher of the Year Award, Medicine Branch and Division of Clinical Sciences, National Cancer Institute
1998	Director's Award, National Institutes of Health
2000	Director's Award, Division of Clinical Sciences, NCI
2010	Director's Award, National Institutes of Health
2010	Director's Award, National Cancer Institute
2023	Director's Award, National Cancer Institute
2024	Director's Award, National Institutes of Health

Extramural Activities

2000-2017	Member, CALGB/Alliance Cooperative Group
2000-2005	Executive Director, Progress Review Group for Lymphoma, Leukemia and Multiple Myeloma
2001	Member, Planning Committee, American Society of Hematology Meeting, 2001
2002-2018	Scientific Advisory Board, International Working Group on non-Hodgkin's Lymphoma (IwNHL)
2005-2006	Committee on Neoplasia, American Society of Hematology
2006-2009	Committee on Lymphoid Neoplasia, American Society of Hematology
2008-2009	Vice-Chair ASH Scientific Committee on Lymphoid Neoplasia
2009-2010	Chair ASH Scientific Committee on Lymphoid Neoplasia

2008-2012	Member, Oncologic Drug Advisory Committee (ODAC), FDA
2009-2014	Scientific Advisory Board, Lymphoma Research Foundation
2009-2018	Member, Lymphoma Steering Committee, Cooperative Groups Cancer Therapy Evaluation Program, NCI, NHI
2010-2012	Chair, Oncologic Drug Advisory Committee (ODAC), FDA

Patents

Methods for identifying, diagnosing, and predicting survival of lymphomas
Patent number: 10697975

ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
Patent number: 8748114

Methods for identifying, diagnosing, and predicting survival of lymphomas
Patent number: 8131475

ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
Patent number: 7981610

ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Patent number: 7329502

Taxol treatment of cancer
Patent number: RE40839

Methods of treating abc-dlbcl using inhibitors of brutons tyrosine kinase
Patent application number: 17881302

Bibliography

1. Wilson WH and Heller HC: Elevated blood glucose levels and satiety in the rat. *Physiol Behav* 15:137-143, 1975.
2. Burton LE, Wilson WH and Shooter EM: Nerve Growth Factor in mouse saliva; Rapid isolation procedures for and characterization of 7 S Nerve Growth Factor. *J Biol Chem* 253:7807-7812, 1978.
3. Wilson WH and Shooter EM: Structural modification of the NH₂-terminus of Nerve Growth Factor; Purification and characterization of Beta-Nerve Growth Factor endopeptidase. *J Biol Chem* 254:6002-6009, 1979.
4. Bothwell MA, Wilson WH and Shooter EM: The relationship between glandular kallikrein and growth factor-processing proteases of mouse submaxillary gland. *J Biol Chem* 254:7287-7294, 1979.
5. Jacobs MB and Wilson W: Iron deficiency anemia in a vegetarian runner. *JAMA* 252(4):481-482, 1984.
6. Lane CH, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with Zidovudine in human immunodeficiency virus infection. *Ann Intern Med* 113:512-519, 1990.
7. Wilson WH, Magrath I: Principles of chemotherapy. In *The Non-Hodgkin's Lymphomas*. I. Magrath, editor, Edward Arnold, publisher, London, 1990.
8. Longo DL, Wilson WH: Follicular lymphomas. In *The Non-Hodgkin's Lymphomas*. I. Magrath, editor, Edward Arnold, publisher, London, 1990.
9. Barriga F, Magrath I, Wilson WH: Complications in the management of non-Hodgkin's lymphomas. In *The Non-Hodgkin's Lymphomas*. I. Magrath, editor, Edward Arnold, publisher, London, 1990.
10. Magrath I, Wilson WH, Horgath M, Neumann R, Barriga F: Clinical features and staging. In *The Non-Hodgkin's Lymphomas*. I. Magrath, editor, Edward Arnold, publisher, London, 1990.
11. Rothenberg M, Wilson W, Chabner BA: Complications of drug therapy for cancer: General review. In *The Complications of Cancer Management*. Plowman, P.N., McElwain, T.J., and Meadows A.T., editors, Butterworth-Heinemann, publishers, U.K., 1991.

12. Chabner BA, Wilson WH: Reversal of multidrug resistance. [Editorial] *J Clin Oncol* 9:4-6, 1991.
13. Burt RK, Sharfman WH, Karp BI and Wilson WH: Mental neuropathy, a harbinger of tumor progression or relapse. *Cancer* 70:877-881, 1992.
14. Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA and Longo DL: Recent NCI lymphoma trials of etoposide-containing combination chemotherapy. *Semin in Oncol* 19:26-32, 1992.
15. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE: Phase I-II Study of high-dose ifosfamide, carboplatin and etoposide (ICE) with autologous bone marrow rescue in lymphomas and solid tumors. *J Clin Oncol* 10:1712-1722, 1992.
16. Bergan R and Wilson WH: Pulmonary toxicity of cancer therapy. *Intern Med* 13:56-65, 1992.
17. Quezado ZMN, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. *Ann Intern Med* 118:31-36, 1993.
18. Wilson WH: High-dose chemotherapy and autologous transplantation with peripheral blood stem cells by Vose J, Armitage J, Kessinger A. [Commentary] *Oncology* 7:33-34, 1993.
19. Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW, O'Shaughnessy JA, Wittes RE, Chabner BA: Paclitaxel administration using portable infusion pumps. [Letter] *J Clin Oncol* 11:2287-2288, 1993.
20. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. *J Clin Oncol* 11:1573-1582, 1993.
21. O'Shaughnessy JA, Cowan KH, Wilson W, Bryant G, Goldspiel B, Gress R, Nienhuis AW, Dunbar C, Sorrentino B, Stewart FM, Moen R, Fox M, Leitman S: Clinical Protocol-Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant with *neo*^R-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. *Human Gene Therapy* 4:331-354, 1993.
22. Walsh TJ, Renshaw G, Andrews J, Kwon-Chung J, Cunnion RC, Pass HI, Taubengenger J, Wilson W and Pizzo PA: Invasive Zygomycosis due to *Conidiobolus incongruus*. *Clin Infect Dis* 19:423-430, 1994.

23. Wilson WH: The role of GM-CSF and G-CSF in stem cell transplantation by Nemunaitis J. [Commentary] *Oncology* 8:17-18, 1994.
24. Chabner BA, Bates SE, Fojo AT, Spolyar M and Wilson WH: Drug resistance in adult lymphomas. *Semin in Oncol* 31:70-87, 1994.
25. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M, Leitman S, Gottesman M, Pastan I, Denicoff A, Noone M, Gress R: Clinical Protocol-Retroviral mediated transfer of the human multidrug resistance gene (mdr-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. *Human Gene Therapy* 5:891-911, 1994.
26. Shilyansky J, Wilson W, Temeck BK and Pass HI: Pulmonary artery-bronchial fistula during lymphoma treatment. [Letter] *J Thoracic and Cardiovascular Surgery*, 108:790-791, 1994.
27. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA: Paclitaxel in doxorubicin or mitoxantrone refractory breast cancer: A phase I/II trial of 96-hour infusion. *J Clin Oncol* 12:1621-1629, 1994.
28. Humphrey RW, Wilson WH: Treatment of non-Hodgkin's lymphoma by Armitage JO. [Commentary] *Abst Clin Care Guidelines* 6:4-5, 1994.
29. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, Wittes RE: A phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. *J Clin Oncol* 13:381-386, 1995.
30. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, Lee JS, Stetler-Stevenson MA, Jaffe E, Solomon D, Wilson WH, Chabner BA, Fojo A and Bates SE: Expression of mdr-1 in refractory lymphoma: Quantitation by PCR and validation of the assay. *Blood* 86:1515-1524, 1995.
31. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. *J Clin Oncol* 13:1985-1994, 1995.
32. Wilson WH, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: A controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. *J Clin Oncol* 13:1995-2004, 1995.

33. Saville MW, Jietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey R, Feigal E, Steinberg SM, Broder S and Yarchoan R: Treatment of HIV-associated Kaposi's Sarcoma with paclitaxel. *Lancet* 346:26-28, 1995.
34. Chabner BA, Wilson WH: Pharmacology and toxicity of antineoplastic drugs. In Williams Hematology, Beutler E., Lichtman M.A., Coller B.S., and Kipps T.J., editors, McGraw-Hill, Inc publishers USA, 1995.
35. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS and Nienhuis AW: Retrovirally-marked CD-34 enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. *Blood* 85:3048-3957, 1995.
36. Cheson BD, Wilson WH: Paclitaxel in the treatment of hematological malignancies. In Paclitaxel in Cancer Treatment. McGurie, W.P. and Rowinsky, E.K., Editors, Marcel Dekkar Inc, Publisher, New York, 1995.
37. Wilson WH: Drug resistance in non-Hodgkin's lymphomas. *Lymphoma Biology and Research* 1:4-5, 1995.
38. Wilson WH, Bates SE, Fojo A, Chabner BA: Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. *J Can Res Clin Oncol* 121 (Suppl 3):25-29, 1995.
38. Wilson WH, Kingma DW, Wittes RE, Greiner TC and Jaffe ES: Association of Lymphomatoid granulomatosis with Epstein-Barr Viral infection of B Lymphocytes and response to alfa-interferon. *Blood* 87:4531-4537, 1996.
39. Burt RK, Wilson WH: Conditioning regimens. In House Officers Manual of Bone Marrow Transplantation. Barrett AJ, Blume KG, et al editors, R.G. Landes Company, publisher, 1996.
40. Prussick R, Horn TD, Wilson WH and Turner MC: A cutaneous eruption associated with ifosfamide, carboplatin and etoposide chemotherapy after recombinant interleukin-1 α pretreatment. *J Amer Acad Derm*, 35:705-709, 1996.
41. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B: Clinical reversal of multidrug resistance. *Oncologist*, 1:269-275, 1996.
42. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, bcl-2 and MIB-1 proliferative antigen to clinical drug resistance in non-Hodgkin's lymphoma. *Blood*, 89:601-609, 1997.

43. Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, Steinberg SM, Wilson WH, Takimoto CH, Kelley MJ, Johnson BE: Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer. *J Clin Oncol* 15:735-743, 1997.
44. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson WH, Fojo AT, Bates SE: Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain reaction assay. *Blood* 89:3795-3800, 1997.
45. Wilson WH, Chabner BA: Principles of therapy. In *The Lymphomas*. G. Canellos, T.A. Lister, J.L. Sklar, editors, W.B. Saunders, Publisher, 1997.
46. Segal BH, Engler HD, Little R, Wilson WH, Freifeld AG, Chanock SJ: Early forscarnt failure in herpes simplex virus infection in a patient with AIDS. *AIDS* 11:552-553, 1997.
47. Molldrem J, Wilson WH: Infusional chemotherapy for non-Hodgkin's lymphoma. *Cancer Invest* 15:465-474, 1997.
48. Wilson WH: The role of dose intensity in the treatment of HIV-associated lymphomas. *N Engl J Med* [letter] 337:1172-1173, 1997.
49. Wilson WH: Principles of chemotherapy. In *The Non-Hodgkin's Lymphomas*. (Second Edition), I. Magrath, editor, Edward Arnold, Publisher, London, 1997.
50. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, Longo DL, Tosato G: The role of Mig, the monokine induced by interferon- γ , and IP-10, the interferon- γ inducible protein 10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. *Blood* 15:4099-4105, 1997.
51. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita Jr. VT: Alternating MOPP and ABVD plus mantle field radiation therapy in patients with massive mediastinal Hodgkin's disease. *J Clin Oncol* 15:3338-3346, 1997.
52. Sandor V, Wilson W, Fojo A, Bates SE: The role of MDR-1 in refractory lymphoma. *Leuk Lymph* 28:23-31, 1997.
53. Jaffe ES, Wilson WH: Lymphomatoid granulomatosis: Pathogenesis, pathology and clinical implications. *Cancer Surv* 30:233-248, 1997.
54. Wilson WH: Pharmacokinetics of chemotherapy agents by continuous infusion: The Paclitaxel Module. In *Infusion Chemotherapy-Radiation Interaction: Its Biology and Significance for Organ Salvage and Prevention of Second Primary Neoplasms*. C.

- Julian Rosenthal and Marvin Rotman, editors, Elsevier, Publisher, Amsterdam, 1998.
55. Mickley LA, Lee JS, Weng Z, Alvarez M, Wilson W, Bates SE, Fojo AT: Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. *Blood* 91:1749-1756, 1998.
 56. Little R, Wittes RE, Longo DL, Wilson WH: Vinblastine in recurrent Hodgkin's disease following autologous stem cell transplant. *J Clin Oncol* 16:584-588, 1998.
 57. Weng DE, Wilson WH, Little RL, Walsh TJ: Successful medical management of isolated renal Zygomycosis: A case report and literature review. *Clin Infect Dis* 26:601-605, 1998.
 58. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill K, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R: Phase II trial with dose titration of paclitaxel for the therapy of Human Immunodeficiency Virus-associated Kaposi's sarcoma. *J Clin Oncol* 16:1112-1121, 1998.
 59. Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, Nieder M, Owen W, Seibel N, Wilson W, Horak ID, Magrath I: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. *Semin Oncology* 25 (Suppl 4):33-39; discussion 45-48, 1998.
 60. Wilson WH, Little R, Pearson D, Jaffe E, Steinberg S, Cheson BD, Humphrey R, Kohler D, Elwood P. A phase II and dose escalation □ G-CSF study of 9-aminocamptothecin in relapsed and refractory lymphomas. *J Clin Oncol* 16:2345-2351, 1998.
 61. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J and Wilson W: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of Amphotericin B (AmBisome) in neutropenic patients. *Antimicrob Agents Chemother* 42:2391-2398, 1998.
 62. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC: Central nervous system involvement in primary mediastinal large B-cell lymphoma. *J Clin Oncol* 17:2479-2485, 1999.
 63. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson MA, Waldman TA, Pastan I: Responses in refractory Hairy Cell leukemia to a recombinant immunotoxin. *Blood* 94:3340-3348, 1999.

64. Cowan KH, Moscow JA, Huang H, Zujewski J, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis: Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. *Clin Cancer Res* 5:1619-1628, 1999.
65. Wilson W: Clinical aspects and treatment in angioimmunoblastic T cell lymphoma (AILD). In *Clinical Implications of the R.E.A.L Classification*. Mason DY and Harris NL, editors. Springer-Verlag, London, Publishers, 1999.
66. Wilson W: Clinical aspects and treatment options in nasal/nasal type lymphoma (angiocentric lymphomas) and lymphomatoid granulomatosis. In *Clinical Implications of the R.E.A.L Classification*. Mason DY and Harris NL, editors. Springer-Verlag, London, Publishers, 1999.
67. Baris D, Kwak L, Rothman N, Wilson W, Manns A, Tarone RE, Hartge P: Blood levels of organochlorines before and after chemotherapy among non-Hodgkin's lymphoma patients. *Cancer Epidemiol Biomarkers and Prev* 9:193-197, 2000.
68. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson MA, Jaffe E, Giardina S, Waldmann TA, Pastan I: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. *J Clin Oncol* 18:1622-1636, 2000.
69. Wilson WH, Sorbara L, Figg WD, Month EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A: Modulation of clinical drug resistance in a B-cell lymphoma patients by the protein kinase inhibitor 7-Hydroxystaurosporine (UCN-01): Presentation of a novel therapeutic paradigm. *Clin Cancer Res* 6:415-421, 2000.
70. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma by gene expression profiling. *Nature* 403:503-511, 2000.
71. Little R, Gutierrez M, Wilson WH: Chemotherapy sensitization by rituximab: Presentation of two case studies. *Case Studies in Oncology* 2:1-7, 2000.
72. Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause GL, Janik JE, Bramen VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ: Combination chemotherapy followed by a recombinant immunotoxin (anti-B4-

- blocked ricin) in patients with indolent lymphomas: Results of a phase II study. *Cancer J Sci Am* 6:146-150, 2000.
73. Bishop PC, Rao VK, Wilson W: Burkitt's lymphoma: Molecular pathogenesis and treatment. *Cancer Invest* 18:574-583, 2000.
 74. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH: The role of retreatment with a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8 year follow-up study of EPOCH. *J Clin Oncol* 18:3633-3642, 2000.
 75. Little RF, Yarchoan R, Wilson WH: Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. *Curr Opin Oncol* 12:438-444, 2000.
 76. Chabner BA, Wilson W, Supko J: Pharmacology and toxicity of antineoplastic drugs. In William's Hematology, 2001.
 77. Wilson WH: Chemotherapy sensitization by rituximab: Experimental and clinical evidence. *Semin Oncol* 27:30-36, 2001.
 78. Gutierrez ME, Grossbard M, Jaffe E, Chabner BA, Wilson WH: Dose-adjusted EPOCH-Rituximab (EPOCH-R): An effective regimen in poor prognosis aggressive B-cell lymphoma. *Biologic Therapy of Lymphoma* 4:10-13, 2001.
 79. Saif MW, Little RF, Hamilton M, Allegra CJ and Wilson WH: Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A case report and review of the literature. *Ann Oncol* 12:123-129, 2001.
 80. Hegde U, Wilson WH: Gene expression profiling of lymphomas. *Curr Oncol Reports* 3:243-249, 2001.
 81. Jaffe ES, Wilson WH: Lymphomatoid Granulomatosis. Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, pg 185-187, 2001.
 82. Leach FS, Gutierrez M, Pavlovich C, Wilson W: Lymphoma of the kidney: A case of mistaken identity. *Infections in Urology* 14:46-48, 2001.
 83. Little RF, Gutierrez M, Jaffe E, Pau A, Horne M, Masur H, Wilson W: HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. *JAMA* 285:1880-1885, 2001.

84. Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M, Wilson WH, Jaffe ES: Cutaneous lymphomatoid granulomatosis: Correlation of clinical and biological features. *Am J Surg Pathol* 25:1111-1120, 2001.
85. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson MA, FitzGerald DJ, Pastan I: High complete remission rate in chemotherapy-resistant classic or variant Hairy Cell Leukemia induced by the anti-CD22 recombinant immunotoxin BL22. *New Engl J Med* 345:241-247, 2001.
86. Pickarz RL, Sandor V, Bakke S, Wilson WH, Dahmouch L, Kingma DM, Turner ML, Atlimus R, Bases SE: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma. *Blood* 98:2865-2868, 2001.
87. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral O, Powell J, Botstein D, Byrd JC, Grever MR, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM: Relation of gene expression phenotype to immunoglobulin mutation genotype in Chronic Lymphocytic Leukemia. *J Exp Med* 194:1639-1647, 2001.
88. Gill R, Van Waes C, Kass E, Wilson W: Lymphomas of the head and neck; In *Otolaryngology and Facial Plastic Surgery. Emedicine* 2:10-15, 2001.
89. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML: Role of rituximab and chemotherapy in aggressive B-cell lymphomas: A preliminary report of dose-adjusted EPOCH-R. *Semin Oncol* 29:41-47, 2002.
90. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F: Dose-adjusted EPOCH chemotherapy in untreated large B-cell lymphomas: A novel pharmacodynamic approach with high efficacy. *Blood* 99:2685-2693, 2002.
91. Rosenwald A, Wright G, Campo E, Chan WC, Fisher RI, Gascoyne R, Muller-Hermelink HK, Smeland EB, Staudt LS, for the Lymphoma/Leukemia Molecular Profiling Project. Author list by Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Consortium Center: Rosenwald A, Wright G, Giltne JM, Hurt EM, Zhao H, Averett L, Yang L, Powell J, Duffey PL, Longo DL, Wilson WH, Jaffe E, Simon R, Klausner RD, Staudt LM et al. Molecular Diagnosis and Clinical Outcome Prediction in Diffuse Large B-cell Lymphoma. *N Engl J Med* 346:1937-1947, 2002.
92. Gutierrez ME, Wilson WH: Salvage chemotherapy of non-Hodgkin's lymphomas. In *Malignant Lymphoma*. B.C. Decker, Inc, London. Salvage Chemotherapy of Non-Hodgkin's Lymphoma. P 289-300.

93. Hegde U, Wilson WH, White T, Cheson BD: Rituximab Treatment of Refractory Fludarabine-associated Immune Thrombocytopenia in Chronic Lymphocytic Leukemia. *Blood* 100:2260, 2002.
94. Staudt L, Wilson WH: Focus on Lymphoma. *Cancer Cell* 2:363, 2002.
95. Bryant-Greenwood PK, Sorbara L, Filie AC, Little R, Yarchoan R, Wilson W, Raffeld M, Abati A: Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's Sarcoma, Castleman's Disease and recurrent pleural effusions. *Mod Path* 16:145, 2003.
96. Little RF, Pittaluga S, Drbohlav N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, and Wilson WH: Highly effective treatment of acquired immunodeficiency syndrome related lymphoma with dose adjusted EPOCH: Impact of anti-retroviral therapy suspension and tumor biology. *Blood* 101:4653, 2003.
97. Leonard GD, Hege U, Butman JH, Jaffe ES, Wilson WH: Extraocular muscle palsies in subcutaneous panniculitis-like T-cell lymphoma. *J Clin Oncol* 21:2993, 2003.
98. Wiestner A, Rosenwald A, Barry T, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Steterler-Stevenson M, Raffeld M, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. *Blood* 101:4944, 2003.
99. Little RF, Wilson WH: Update on the pathogenesis, diagnosis and therapy of AIDS-related lymphoma. *Curr Infect Dis Rep* 5:176, 2003.
100. Rosenwald A, Wright G, Weistner A, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne R, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe E, Simon R, Klausner RD, Montserrat E, López-Guillermo A, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The Proliferation Gene Expression Signature is a Quantitative Integrator of Oncogenic Events that Predicts Survival in Mantle Cell Lymphoma. *Cancer Cell* 3:185, 2003.
101. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. *BBMT* 9:162, 2003.

102. Nguyen JD, Carrasquillo JA, Little RF, Ryan QC, Wilson W, Chen CC. Fluoro-deoxyglucose positron emission tomography in the presence of cardiac metastases. *Clin Nucl Med* 28:979, 2003.
103. Wilson WH: Commentary: DNA Microarrays in Lymphoid Malignancies. *Oncology* 17:1759, 2003.
104. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, López-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 198:851, 2003.
105. Murdock J, Jaffe ES, Wilson WH, McManus DT et al: Aggressive natural killer cell leukemia/lymphoma: Care report, use of telesynergy and review of the literature. *Leukemia and Lymphoma* 45:1269, 2004.
106. Hegde U, Wilson WH: New Treatment Strategies in Chronic Lymphocytic Leukemia. In Treatment of Chronic Lymphocytic Leukemias. In Chronic Lymphocytic Leukemia: Pages 315-328. Editor Faguet G.B, Human Press, Totowa, New Jersey. 2004.
107. Jaffe ES and Wilson WH: Grey zone, synchronous and metachronous lymphomas: Diseases at the interface of Hodgkin and non-Hodgkin lymphomas. Non-Hodgkin's Lymphomas. Eds. Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R and Harris NL. Lippincott Williams and Wilkins Publisher, Philadelphia, 2004.
108. Dunleavy K, Staudt LM, Wilson WH: Clinical Applications of Molecular Profiling in Lymphomas. Progress in Oncology. Eds. Devita VT, Hellamn S and Rosenberg SZ. Jones and Bartlett Publishers, Sudbury, Massachusetts, 2004.
109. Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Drbohlav N, Gutierrez M, Waldmann TA, Wilson WH: Serum soluble interleukin-2 receptor levels are elevated in patients with anaplastic large cell lymphoma. *Blood* 104:3355, 2004.
110. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Botstein D, Brown PO, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM: Fludarabine Treatment of Chronic Lymphocytic Leukemia Patients Induces a p53-Dependent Gene Expression Response. *Blood* 104:1428, 2004.

111. Mattu R, Sorbara L, Filie A, Little R, Wilson W, Raffeld M, Abati A: Utilization of Polymerase Chain Reaction on Archival Cytologic Material: a Comparison with Fresh Material with Special Emphasis on CSFs. *Mod Path* 17:1295, 2004.
112. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp P, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM: Survival Following Diagnosis of Follicular Lymphoma is Predicted by Molecular Features of Non-malignant Tumor-infiltrating Immune Cells. *New Eng J Med* 351:2159, 2004.
113. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, Wilson WH: Non-Hodgkin's lymphoma in Job's syndrome: A case report and literature review. *Leukemia and Lymphoma* 45:2521, 2004.
114. Little R, Gutierrez M, Wilson WH: Non-Hodgkin's Lymphoma. *Clinical Hematology*, Elsevier, 2004.
115. Wilson W, Supko J: Pharmacology and Toxicity of Anti-Neoplastic Agents. *Hematology*, eds. Williams, 2004.
116. Wilson WH. Principals of Treatment in "The Lymphomas". 2nd Edition. Editors: Canellos G, Lister TA, and Young B. Saunders. 2004.
117. Chabner BA, Wilson W, Supko J: Pharmacology and Toxicity of Anti-Neoplastic Agents. Goodman and Gilman, 2004.
118. Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. *Transfusion* 44:1679, 2004.
119. Grube M, Rezvani M, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA. Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. *Clin Ca Res* 10:1047, 2004.
120. Lunning MA, Zenger VE, Dreyfuss R, Stetler-Stevenson M, Rick ME, White TA, Wilson WH, Marti GE: Albumin enhanced morphometric image analysis in CLL. *Cytometry B Clin Cytom* 57:7, 2004.
121. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson MA, Wilson WH: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive

- B-cell lymphomas at risk of central nervous system involvement: The role of flow cytometry versus cytology. *Blood* 105:496, 2005.
122. Gutierrez M, Little R, Wilson WH: Non-Hodgkin's Lymphoma. *Bethesda Handbook of Clinical Oncology*. Second edition. Editors Abraham J, Allegra CJ and Gulley J. Lippincott Williams and Wilkins, 28:357-375, 2005.
 123. Abraham J, Wilson W, Jaffe E: Hodgkin's Lymphoma. *Bethesda Handbook of Clinical Hematology*. Editors Rodgers GP and Young NS. Lippincott Williams and Wilkins, 15:186-198, 2005.
 124. Little RF, Gutierrez M, Wilson WH. Non-Hodgkin's Lymphoma. *Bethesda Handbook of Clinical Hematology*. Editors Rodgers GP and Young NS. Lippincott Williams and Wilkins, 16:199-220, 2005.
 125. Patsalides A, Hegde U, Butman JA, Jaffe E, NJ Patronas NJ, Wilson WH: Central nervous system radiological abnormalities in lymphomatoid granulomatosis. *Radiology* 237:265-273, 2005.
 126. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell Recovery Following Rituximab-Based Therapy Is Associated with Perturbations in Stromal Derived Factor-1 and Granulocyte Homeostasis. *Blood* 106:795, 2005.
 127. Dunleavy K, Wilson WH: Lymphomas in *American College of Physicians Medicine*. Section 12, 2005.
 128. Neelapu SS, Kwak LW, Kobrin CB, Janik J, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg S, Gress R, Hakim F, Wilson WH: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. *Nat Med* 11:986-991, 2005.
 129. Ahmad E, Kingma DW, Jaffe ES, Schrag JA, Janik J, Wilson W, Stetler-Stevenson MA. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. *Cytometry B Clin Cytom*. 67:6-12, 2005.
 130. Kreitman RJ, Squires DR, Stetler-Stevenson AM, Noel P, FitzGerald DJP, Wilson WH and Pastan I. Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients with B-cell Malignancies. *J Clin Oncol* 23:6719-6729, 2005.
 131. Fu K, Weisenburger DD, Greiner TC, Dave S, Chiorazzi M, Wright G, Gesk S, Siebert R, De Jong D, Jaffe ES, Delabie J, Ott G, Wilson W, Brazziel RM, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK, Campo E, Gascoyne RD, Rosenwald A, Staudt LM, and Chan WC: Cyclin D1-Negative Mantle Cell

- Lymphoma: A Gene Expression Profiling, Genetic and Clinicopathological Study. *Blood* 106:4315, 2005.
132. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR: Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy-Refractory Non-Hodgkin's Lymphoma. *Biol Blood Marrow Transplant* 11:593, 2005.
 133. Wilson WH: R-CHOP Strikes Again with Survival Benefit in Follicular Lymphoma: Where do we go from here? *Blood* 106: 3678-3679, 2005.
 134. Wilson WH: Long Term Results of the R-CHOP Study in Elderly Patients with DLBCL. *Am J Oncology Rev* 4:650-650, 2005.
 135. Aurrant-Schlein T, Telford W, Perfetto S, Caporaso N, Wilson W, Stetler-Stevenson MA, Zenger VE, Abbasi F, Marti GE. Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia. *Leukemia* 19:2339-2341, 2005.
 136. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A: Diffuse Large B Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction. *Blood* 106:3183, 2005.
 137. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Wilson WH, Robinson MR: The Pharmacokinetics of Rituximab following an Intravitreal Injection. *Exp. Eye Res.* 82:760, 2006.
 138. Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ: Radiofrequency Ablation of Lymphoma. *Blood* 107:1624, 2006.
 139. Chabner BA, Amrein PC, Druker B, Michaelson MD, Mitsiades CS, Goss PE, Ryan DP, Ramachandra S, Richardson PG, Supko JG and Wilson WH: Chemotherapy of Neoplastic Diseases: Antineoplastic Agents in *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. Eleventh edition. Editors Brunton LL, Lazo JS and Parker. McGraw-Hill, New York. 51:1315-1404, 2006.
 140. Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, Tretler J, Fleisher T, Puck JM, Wilson W, Jaffe ES, Avila N, Chen CC, Straus SE. Fluorodeoxyglucose Positron Emission Tomography (FDG PET) for Monitoring Lymphadenopathy in the Autoimmune Lymphoproliferative Syndrome (ALPS). *Amer J Heme* 81:81, 2006.

141. Schinstine M, Filie AC, Wilson W, Stetler-Stevenson MA, and Abati A: Detection of Malignant Hematopoietic Cells in Cerebral Spinal Fluid Previously Diagnosed as Atypical or Suspicious. *Cancer* 108:157, 2006.
142. Dunleavy K, Wilson WH: The Case for Rituximab in AIDS-Related Lymphoma. *Blood* 107:3014-3015, 2006.
143. Dave SS, Fu K, Wright GE, Lam LT, Greiner TC, Weisenburger DD, Kluin P, Boerma EJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Vose J, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM for the Leukemia Lymphoma Molecular Profiling Project: Molecular Diagnosis of Burkitt Lymphoma. *N Engl J Med* 354:2431, 2006.
144. Kreitman RJ, Wilson WH, Pastan I: Complete Remissions of Purine Analog-Resistant Hairy Cell Leukemia Induced by the Anti-CD22 Recombinant Immunotoxin BL22. Trends in Diphtheria Research, Nova Science Publishers, Inc, Hauppauge, New York, 2006.
145. Bernstein WB, Little RF, Wilson WH, Yarchoan R: AIDS-Related Malignancies in the HAART Era. *Int. J. Hematol* 83:3, 2006.
146. Wayne A, Wilson WH: Burkitt and Lymphoblastic Lymphoma. Lymphoma: Diagnosis and Treatment. Editors Marcus R, Sweetenham J and Williams M. Cambridge University Press, Cambridge, 2006.
147. Dunleavy K, Wilson WH: Primary Intraocular Lymphoma: Current and Future Perspectives. *Leukemia and Lymphoma* 47:1726, 2006.
148. Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M. International Central Nervous System & Ocular Lymphoma Workshop: Recommendations for the future. *Ocul Immunol Inflamm.* 14:139, 2006.
149. Wilson WH. Drug Resistance in Diffuse Large B-cell Lymphoma. *Semin Heme* 43:230, 2006.
150. Ise T, Nagata S, Kreitman RJ, Wilson WH, et al: Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. *Leukemia* 21:169, 2007.
151. Dunleavy K, Davis E, Landgren O, Staudt LM, Wilson WH: BCL-6 and Rituximab in Diffuse Large B-cell Lymphoma: Where are we? *Blood* 109:843, 2007.

152. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, et al: A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. *Clin Cancer Res* 13:958, 2007.
153. Kelloff GJ, Sullivan DM, Wilson W, et al: FDG-PET Lymphoma Demonstration Project Invitational Workshop. *Academic Radiology* 14:330, 2007.
154. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES and Staudt LM for the Lymphoma/Leukemia Molecular Profiling Project: Point mutations and genomic deletions in *Cyclin D1* create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. *Blood* 109:4599, 2007.
155. Dunleavy K, Wilson WH: Angioimmunoblastic T-cell Lymphoma: Immune Modulation as a Therapeutic Strategy. *Leukemia and Lymphoma* 48:449, 2007.
156. Dunleavy K, Wilson WH, Jaffe ES: Angioimmunoblastic T-cell Lymphoma (AITL): Pathobiological Insights and Clinical Implications. *Curr Opin Hematol* 14:348, 2007.
157. Dunleavy K, Staudt LM, Wilson WH: The Bcl-2 Biomarker in the Era of Molecular Diagnosis of Diffuse Large B-cell Lymphoma. *Leukemia and Lymphoma* 48:1061, 2007.
158. Dunleavy K, Wilson WH: Diagnosis and Treatment of Non-Hodgkin Lymphoma (Aggressive). Hoffman Text Book of Hematology, 2007.
159. Wilson WH and Armitage J: Non-Hodgkin's Lymphoma. Clinical Oncology, Ed Abeloff et al.
160. Wilson WH: International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. *Cytometry B Clin Cytom.* 2007;72 Suppl 1:S2.
161. Wilson WH: 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. Editorial, 72B:S2, 2007.
162. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol.* 26:4124-30, 2008.

163. Hwang S, Janik J, Jaffe ES, Wilson WH: Cutaneous T-cell Lymphomas. *Lancet* 371:945, 2008.
164. Buske C, Gisselbrecht C, Gribben J, Letai T, Mclaughlin P, Wilson W. Refining the treatment of follicular lymphoma. *Leukemia and Lymphoma* 49:18-26, 2008.
165. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A and Rader C: Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia. *Clin Cancer Res* 14:396, 2008.
166. Wilson WH, Dunleavy K, Pittaluga S, et al: Dose-Adjusted EPOCH-Rituximab in Untreated Germinal Center and Post-Germinal Center Diffuse Large B-cell Lymphoma. *J Clin Oncol* 26:2717-2724, 2008.
167. Ahmad E, Steinberg SM, Goldin L, Hess CJ, Caporaso N, Kreitman RJ, Wiestner A, Wilson W, White T, Marti G, Stetler-Stevenson MA: Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. *Cytometry B Clin Cytom.* 74:221-226, 2008.
168. Shanti RM, Torres-Cabala CA, Jaffe ES, Wilson WH, Brahim JS. Lymphomatoid Granulomatosis With Involvement of the Hard Palate: A Case Report. *J Oral Maxillofac Surg.* 66:2161-2163, 2008.
169. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, Quijano S, Stetler-Stevenson MA, Subira D, Wilson W. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid. *Current Protocols in Cytometry* 6.25.1-6.25.16, 2008.
170. Pittaluga S, Wilson WH, Jaffe ES: Lymphomatoid Granulomatosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Editors Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer, Lyon, 2008. Pages 247-249.
171. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, Quijano S, Stetler-Stevenson M, Subira D, Wilson W. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid. *Curr Protoc Cytom.* 2008 Jul; Chapter 6:Unit 6.25.
172. O'Mahoney D, Peikarz RL, Bandettini WP, Arai AE, Wilson W, Bates SE. Cardiac involvement with lymphoma: a review of the literature. *Clin Lymphoma Myeloma.* 8:249-52, 2008.
173. Rizzo K, Stetler-Stevenson M, Wilson W, Yuan CM: Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation. *Cytometry B Clin Cytom.* 76:142-9, 2008.

174. Young KH, Leroy K, Møller MB, Colleoni GWB, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. *Blood*. 112:3088-3098, 2008.
175. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood*. 111:5496-504, 2008.
176. Hoover SE, Kawada J, Wilson W, Cohen J: Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. *J Infect Dis*. 198:318-323, 2008.
177. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink H-K, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal Gene Signatures in Large-B-Cell Lymphomas. *N Engl J Med* 359:2313-2323, 2008.
178. Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F, Valdez J, Samsel L, McCoy JP Jr, Wilson W, Pittaluga S, Wiestner. Lenalidomide Induced Upregulation of CD80 on Tumor Cells Correlates with T-cell Activation, the Rapid Onset of a Cytokine Release Syndrome and Leukemic Cell Clearance in Chronic Lymphocytic Leukemia. *Haematologica*. 94:1266-73, 2009.
179. Dunleavy K, Pittaluga S, Czuczman M, Dave S, Wright G, Grant N, Shovlin M, Jaffe ES, Janik J, Staudt LM, Wilson WH: Differential Efficacy of Bortezomib Plus Chemotherapy Within Molecular Subtypes of Diffuse Large B Cell Lymphoma. *Blood*. 113:6069-76, 2009.
180. Kochenderfer JN, Feldman SA, Zhao Y, Xu Y, Black MA, Morgan A, Wilson WH, Rosenberg SA. Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. *J Immunother*. 32:689-702, 2009.
181. Kreitman R, Stetler-Stevenson MA, Margulies I, Noel P, FitzGerald DJP, Wilson WH, Pastan I. Phase II Trial Of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) In Patients With Hairy Cell Leukemia. *J Clin Oncol*. 27:2983-90, 2009.

182. Little RF, Wilson WH. Non-Hodgkin's Lymphoma. The Bethesda Handbook of Clinical Hematology, edited by Drs. Rodgers and Young. 2009.
183. Dunleavy K, Wilson WH: HIV-Associated Lymphoid Neoplasms. The Lymphoid Neoplasms, 3rd Edition. Editor Ian Magrath. Hodder Arnold, London, 2009.
184. Jaffe ES, Wilson WH: Borderlines between Pathologic Entities: Composite Lymphomas. The Lymphoid Neoplasms, 3rd Edition. Editor Ian Magrath. Hodder Arnold, London, 2009.
185. Jiang L, Yuan C, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M. Variable CD52 Expression in Mature T Cell and NK Cell Malignancies: Implications for Alemtuzumab Therapy. *Br J Haematol.* 45:173-9, 2009.
186. Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W: Refining the treatment of follicular lymphoma. *Leuk and Lymphoma* 48:18, 2009.
187. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. *Haematologica* 94:1259-65, 2009.
188. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. *Ann Oncol.* 20:715-21, 2009.
189. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. *Semin Oncol.* 36(4 Suppl 2):S35-45, 2009.
190. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. *Haematologica.* 94:1259-65, 2009.
191. Landgren O, Dunleavy K, Wilson WH. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. Letter. *J Natl Cancer Inst.* 101:1287-8, 2009.
192. Tay K, Dunleavy K, Wilson WH. Targeting HLA-DR. *Leuk and Lymphoma* 50:1911-1913, 2009.

193. Jiang L, Abati AD, Wilson W, Stetler-Stevenson M, Yuan C. Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up. *Int J Clin Exp Pathol.* 15:110-116, 2009.
194. Davis RE, Ngo V, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Z, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang J, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink K, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Wilson W, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell receptor signaling in diffuse large B-cell lymphoma. *Nature* 463:88-94, 2010.
195. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH. The Role of Tumor Histogenesis, FDG-PET and Short Course EPOCH with Dose Dense Rituximab (SC-EPOCH-RR) in HIV-Associated Diffuse Large B-cell Lymphoma. *Blood* 115:3017-3024, 2010.
196. Tay K, Dunleavy K, Wilson WH: Novel agents for B-cell non-Hodgkin's lymphoma: Science and promise. *Blood Rev* 24:69-82, 2010.
197. Roschewski M, Wilson WH. Biology and Management of Rare Primary Extranodal T-cell Lymphomas. *Oncology* 24:94-100, 2010.
198. Leshchenko V, Kuo P, Shaknovich R, Yang DT, Gellen T, Pêche H, Yu Y, Remache Y, Weniger M, Rafiq S, Suh S, Goy A, Wilson W, Verma A, Muthusamy N, Kahl B, Byrd J, Wiestner A, Melnick A, Parekh S. Genome wide DNA Methylation Analysis reveals novel targets for drug development in Mantle cell lymphoma. *Blood* 116:1025-1034. 2010.
199. Dunleavy K, Tay K, Wilson WH. Rituximab Associated Neutropenia. *Semin Heme* 47:180-186, 2010.
200. Moriyama B, Falade O, Leung J, Penzak SR, Jingo CJ, Huang X, Henning SA, Masur H, Wilson WH, Walsh TJ. Prolonged Half-life of Voriconazole in a CYP2C19 Homozygous Poor Metabolizer Receiving Vincristine Chemotherapy: Avoiding a Serious Adverse Drug. *Ann Pharmacother* 44:929-935, 2010.
201. Dunleavy K, Wilson WH. Role of Molecular Subtype in Predicting Outcome of AIDS-Related Diffuse Large B-cell Lymphoma. Letter. *J Clin Oncol* 28:260, 2010.
202. Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH, Spector N, Milito C, Morais JC, Jaffe ES. Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression. *Am J Surg Pathol.* 34:1425-35. 2010.

203. Dunleavy K, Wilson WH. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma. *Leuk Lymphoma*. 51:1347-1350. 2010.
204. Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE. New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. *Clin Cancer Res*. 2010 Dec 1;16(23):5608-17.
205. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. *Blood* 116:4099-4102. 2010.
206. Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. *Leuk Lymphoma*. 51 Suppl 1:28-33. 2010.
207. Dunleavy K, Wilson WH. Chapter 88: HIV-Associated Lymphoid Neoplasms. *The Lymphoid Neoplasms, 3rd Edition*. Edited by Ian Magrath. (Hodder Arnold). Publication Spring 2010.
208. Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma. *Leuk Lymphoma* 51 Suppl 1:1-10. 2010.
209. Wilson WH, O'Connor OA, Czuczman MS et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. *Lancet Oncol* 11:1149-1159. 2010.
210. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. *Curr Opin Hematol*. 2010 Nov 22. [Epub ahead of print].
211. Savan R, Reynolds DA, McFarland AP, Feigenbaum L, Ramakrishnan K, Shirota H, Klinman DM, Dunleavy KM, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA. Ectopic expression of IL-22R1 on lymphocytes results in systemic inflammation in mice: A model for ALK+ anaplastic large cell lymphoma. *Blood* 117:575-584. 2011.
212. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari S, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson MA, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A. The lymph node microenvironment promotes B-cell receptor signaling, NF- κ B activation, and tumor proliferation in chronic lymphocytic leukemia. *Blood* 117:563-574. 2011.

213. Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti E, Chapman CM, Mo C, Stennett L, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy K, Wilson WH, Staudt LM, Wiestner A. Bortezomib resistance in Mantle Cell Lymphoma is associated with plasmacytic differentiation. *Blood*, 117:542-552. 2011.
214. Dunleavy K, Wilson WH. Diagnosis and Treatment of Non-Hodgkin Lymphoma (Aggressive). Hoffmann Hematology: Basic Principles and Practices 5th Edition 2011. (Elsevier Saunders).
215. Dunleavy K, Wilson WH. Chapter XI. Malignant Lymphomas. American College of Physicians (ACP) Medicine Textbook. Published 2011.
216. Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA and Jaffe ES. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. *Blood* 117:1447-1452. 2011.
217. Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. *Leuk Lymphoma*. 2011 Jan;52(1):24-33.
218. Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, Adams LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, Staudt LM, Emmert-Buck MR, Jaffe ES. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. *Haematologica* 96:558-566. 2011.
219. Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, Dunleavy K, Pittaluga S, Jaffe ES. Coexisting and Clonally Identical Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma. *Am J Surg Pathol* 35:767-772. 2011.
220. Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning SA, Wilson WH, Walsh TJ. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. *Mycoses*. 2011 Nov;54(6):e877-9.
221. Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. *Leuk Lymphoma*. 2011 Jun;52 Suppl 2:82-6.
222. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? *Curr Hematol Malig Rep*. 2011 Sep;6(3):157-63.

223. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. *Cytometry B Clin Cytom*. 2011 Sep;80(5):309-17.
224. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Methodological comparison of two anti-ZAP-70 antibodies. *Cytometry B Clin Cytom*. 2011 Sep;80(5):300-8.
225. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. *Blood*. 2011 Jun 2;117(22):5835-49.
226. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. *Blood*. 2011 Mar 24;117(12):3402-8.
227. Dunleavy K, Wilson WH. Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma. *Clin Cancer Res*. 2011 Dec 15;17(24):7505-7.
228. Eberle FC, Salaverria I, Steidl C, Summers TA Jr, Pittaluga S, Neriah SB, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. *Mod Pathol*. 2011 Dec;24(12):1586-97.
229. Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH. Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2011 Dec;52(12):2284-92.
230. Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. *Clin Cancer Res*. 2011. 17:5101-5112.
231. Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, Keyvanfar K, Lee E, Wilson W, Wiestner A. Activation of CD44, a receptor for

extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. *Leuk Lymphoma*. 2011. 52:1758-1769.

232. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*. 2012. 119:2709-2720.
233. Dunleavy K, Kass E, Wilson WH. Emedicine. Otolaryngology and Facial Plastic Surgery. Lymphomas of the head and neck. 2012.
234. Dunleavy K, Grant C, Wilson WH. Lymphomas (Emerging Cancer Therapeutics V3 12 by Sweetenham (Demos Medical) Published 11/2012. Chapter 5. 'Novel Pathways and Therapeutic Strategies for Aggressive B-Cell Lymphomas'.
235. Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. *MAbs*. 2012. 4::349-361
236. Roschewski M, Wilson WH. EBV-associated lymphomas in adults. *Best Pract Res Clin Haematol*. 2012. 25:75-89.
237. Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, Pittaluga S, Jaffe ES. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. *Am J Surg Pathol*. 2012. 36:716-725.
238. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. *J Clin Oncol*. 2012. 30:1822-1828.
239. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. *Blood*. 2012. 119:3245-3255.
240. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED; for the Cancer Leukemia Group B A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. *Haematologica*. 2012. 97:758-765.
241. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Combined normal donor and CLL: Single tube ZAP-70 analysis. *Cytometry B Clin Cytom*. 2012. 82:67-77.

242. Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR: Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. *J Clin Oncol*. 2012. 30:830-836.
243. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular targeted therapy. *Int J Hematol*. 2012. 96:552-561.
244. Roschewski M, Wilson WH. Lymphomatoid Granulomatosis. *Cancer J*. 2012. 18:469-474.
245. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. *Blood*. 2012. 120:3501-9.
246. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. *Cancer Res*. 2012. 72:5307-5316.
247. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Olgwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*. 2012. 490:116-120.
248. Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? *Curr Hematol Malig Rep*. 2012. 7:241-247.
249. Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. *Curr Hematol Malig Rep*. 2012. 7:208-215.
250. Dunleavy K, Grant C, Wilson WH. Primary Mediastinal B-Cell Lymphoma. Lymphoma Diagnosis and Treatment (Current Clinical Oncology). (Humana Press). Edited by Younes/Coiffier. 2013.

251. Mo C, Roschewski M, Dunleavy K, Wilson WH. Chapter 28 Non-Hodgkin lymphoma. Bethesda Handbook of Clinical Oncology 4th Edition. Lippincott, Williams and Wilkins. 2013.
252. Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. *Therapeutic Advances in Haematology*. February 2013. 4:43-57.
253. Dunleavy K, Wilson WH. Chapter 81. Diagnosis and Treatment of Diffuse-Large B-Cell lymphoma and Burkitt lymphoma. Hoffman Hematology: Basic Principles and Practices 6th Edition 2013. (Elsevier Saunders).
254. Wilson W, Schenkein D, Jernigan C, Woodcock J, Schilsky R. Re-evaluating the Accelerated Approval Process for Oncology Drugs. *Clin Cancer Res*. 2013. 19:2804-2809.
255. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-Adjusted-EPOCH-R Therapy in Primary Mediastinal B-cell Lymphoma. *N Eng J Med* 2013. 368:1408-1416.
256. Kantarjian H, Wilson W, Ravandi F, Estey. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? *J Clin Oncol* 2013. 31:1795-1796.
257. Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, Hartmann E, Salaverria I, Beà S, Martín-Subero JI, Rosenwald A, Ott G, Wiestner A, Wilson WH, Campo E, Hernández L. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. *Clin Cancer Res*. 2013. 19:3121-3129.
258. Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Bcl-2 level as a biomarker for 13q14 deletion in CLL. *Cytometry B Clin Cytom*. 2013. 84:237-247.
259. Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH, Taylor RP, Wiestner A. Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. *Haematologica*. 2013. 98:1259-1263.
260. Lai C, Wilson W. T-cell lymphoma. *Best Pract Res Clin Haematol*. 2013. 26:1.
261. Bax HI, Freeman AF, Anderson VL, Vesterhus P, Laerum D, Pittaluga S, Wilson WH, Holland SM. B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency. *J Clin Immunol*. 2013. 33:1062-1066.

262. Wilson WH, Grant C, Dunleavy K. Therapy in primary mediastinal B-cell lymphoma. *N Engl J Med*. 2013. 369:283-284.
263. Dunleavy K, Wilson WH. Implications of the shifting pathobiology of AIDS-related lymphoma. *J Natl Cancer Inst*. 2013. 105:1170-1171.
264. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. *Blood*. 2013. 122:2412-2424.
265. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. *Blood*. 2013. 122:3251-3262.
266. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. *Clin Cancer Res*. 2013. 19:6313-6321.
267. Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-García D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. *Proc Natl Acad Sci U S A*. 2013. 110:18250-18255.
268. Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjan JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated JAK/STAT pathways in hematological malignancies. *Leuk Lymphoma*. 2014. 55:1968-1979.
269. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nat Rev Clin Oncol*. 2014. 11:12-23.
270. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. *N Engl J Med*. 2013. 369:1915-1925.

271. Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. *Clin Cancer Res*. 2013. 19:6873-6881.
272. Wilson WH. Treatment strategies for aggressive lymphomas: what works? *Hematology Am Soc Hematol Educ Program*. 2013. 584-590.
273. Wilson WH, Bromberg JEC, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A. The Outcome of Diffuse Large B-cell Lymphoma and Burkitt Lymphoma at Risk of Leptomeningeal Disease. *Haematologica* 2014. 99:1228-1235.
274. Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K. A prospective study of mediastinal Gray Zone Lymphoma. *Blood* 2014. 124:1563-1569.
275. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. *Haematologica* 2014 99:1731-1737.
276. Mena E, Lindengerg ML, Turkbey BI, Shih J, Logan J, Adler S, Wong K, Wilson W, Choyke PL, Kurdziel KA. A pilot study of the value of 18F-Fluoro-Deoxy-Thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. *Clin Nucl Med* 2014 39:874-881.
277. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatazis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood* 2014. 124:1473-1480.
278. Tsai HT, Pfeiffer RM, Warren J, Wilson W, Landgren O. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2015 56:682-687.
279. Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. *Oncology* 2014. 28:326-334.
280. Roschewski M, Manasanch EE, Wilson WH. Management of heavy chain diseases: the challenges of biologic heterogeneity. *Oncology* 2014. 28:63-65.

281. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. *Lancet Oncol*. 2015. 16:541-549.
282. Roschewski M, Wilson WH. Cracking the diverse biologic code of diffuse large B-cell lymphoma. *Semin Hematol*. 2015 52:55-65
283. Leshchenko VV, Kuo PY, Jiang Z, Weniger MA, Overbey J, Dunleavy K, Wilson WH, Wiestner A, Parekh S. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. *Oncotarget*. 2015 6:27332-27342.
284. Moraitis AG, Freeman LA, Shamburek RD, Wesley R, Wilson W, Grant CM, Price S, Demosky S, Thacker SG, Zarzour A, Hornung RL, Pucino F, Csako G, Yarboro C, McInnes IB, Kuroiwa T, Boumpas D, Rao VK, Illei GG, Remaley AT. Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. *J Clin Lipidol*. 2015 9:81-90.
285. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? *Blood*. 2015. 125:33-39.
286. Song JY, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L, Davies-Hill T, Raffeld M, Wilson WH (co-senior author), Jaffe ES. Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. *Am J Surg Pathol*. 2015 39:141-156.
287. Dunleavy K, Roschewski M, Wilson WH. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. *Clin Cancer Res*. 2014 20:5182-5193.
288. Wilson WH, Young RM, Schmitz R, et al. Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma. *Nat Med* 2015 21:922-926.
289. Gharwan H, Lai C, Grant C, Dunleavy K, Steinberg SM, Shovlin M, Fojo T, Wilson WH. Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. *Leuk Lymphoma* 2016 57:1616-1624.
290. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. *Haematologica* 2016, 101:531-540.

291. Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A. Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. *Blood* 2016, 128:82-92.
292. Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. *Blood* 2016 127:3127-32.
293. Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA. Central nervous system involvement in AIDS-related lymphomas. *Br J Haematol* 2016, 173:857-866.
294. Wilson WH. Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. *N Engl J Med*. 2016, 374:386-388.
295. Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, Jaffe ES, Wilson WH. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. *Haematologica* 2016, 101:27-29.
296. Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson W, Waldmann TA, Pastan I. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. *Clin Cancer Res*. 2016, 22:310-318.
297. Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. *J Natl Cancer Inst*. 2016, 108:1-8.
298. Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. *Hematol Oncol Clin North Am*. 2016, 30:P1333-1343.
299. Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJ, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI. *Cancer Cell*. 2016, 30:806-821.
300. Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland, SM, Wilson, W, Dunleavy K, Shah NN, Freeman AF. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. *Front. Pediatr*. 2017, 5:38.

301. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. *Nat Rev Clin Oncol*. 2017. 14:335-346.
302. Lionakis MD, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma. *Cancer Cell* 2017, 31:833.
303. Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg S, Dunleavy K, Pack S, Jaffe ES, and Wilson WH. MYC Gene Rearrangement In Diffuse Large B-cell Lymphoma Does Not Confer a Worse Prognosis Following Dose-Adjusted-EPOCH-R. 2017. *Leukemia and Lymphoma* 2018, 59:505.
304. Melani,C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA Pollyea DA, Smith CA Wilson WH (corresponding author), Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma, *N Engl J Med* 2017, 377:89.
305. Navarro, A, Clot G, Martinez-Trillos A, Pinyol M, Jares P, Gonzalez-Farre B, Martinez D, Trim N, Gernandez V, Villamor N, Colomer D, Costa D, Salaverria I, Martin0-Garcia D, Erber W, Lopez C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, Lopez-Guillermo A, Sanchez A, Campo E, Matutes E, Bea S. Improved Classification of Leukemic B-cell Lymphoproliferative Disorders Using a Transcriptional and Genetic Classifier. *Haematologica* 2017, 102:e360.
306. Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. *Leuk Lymphoma* 2018, 59:1466.
307. Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Barrato L, Steinberg SM, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH. End-of-Treatment and serial PET imaging in Primary Mediastinal B-Cell Lymphoma following dose-adjusted EPOCH-R; a paradigm shift in clinical decision making. *Haematologica* 2018, 103:1337.
308. Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tajeja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats

- JJ, Landgren O. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. *Blood Adv.* 2017, 1:1911.
309. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. *Blood* 2018, 131:2331.
310. Melani C, Wilson WH, Roschewski M. What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? *Br J Haematol.* 2019, 184:836.
311. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2018, 378:1396.
312. Dunleavy K, Fanale MA, Abramson J, Noy A, Fabrizio-Caimi P, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Sterling-Lord R, Lechowicz MJ, Gaur R, Leach JW, Lucas A, Melani C, Steinberg SM, Kahl B, Friedberg JW, Roschewski M, Little RF, Bartlett NL, and Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. *Lancet Haematol* 2018. 5:609.
313. Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. *Nature* 2018, 560:387.
314. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. *Leukemia* 2018. 32:1768.

315. Melani C, Roschewski M, Wilson WH. End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams *et al.* *Haematologica* 2018.103:382.
316. Wright GW, Wilson WH, Staudt LM. Genetics of Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2018. 379:493.
317. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2018. 36:2845.
318. Ben-Yakov G, Alao H, Haydek JP, Fryzek N, Cho MH, Hemmati M, Samala V, Shovlin M, Dunleavy K, Wilson W, Jones EC, Rotman Y. Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. *Hepatol Commun* 2018. 3:220.
319. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab *versus* ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. *Haematologica* 2019. 104:65.
320. Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. *Blood* 2019. 133:1313.
321. Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. *Leuk Lymphoma* 2019. 60:2062.
322. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Reply to J. Wang *et al.* *J Clin Oncol* 2019. 37:755.

323. Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS. Viral, immunologic, and clinical features of primary effusion lymphoma. *Blood* 2019. 133:1753.
324. Wilson WH. Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' reply. *Lancet Haematol* 2019. 6:120.
325. Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoiloova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattonne CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2019. 37:1285.
326. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *J Clin Oncol* 2019. 37:1790.
327. Melani C, Wilson WH, Roschewski M. Liquid biopsy in non-Hodgkin's lymphoma. *Hematol Oncol* 2019. 37:70-74.
328. Miljkovic MD, Roschewski M, Dunleavy K, Wilson WH. Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma. *Leuk Lymphoma* 2019.
329. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. *Cell* 2019. 178:699.
330. Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. *Immunol Rev* 2019. 291:190.
331. Rossi D, Kurtz DM, Roschewski M, Cavalli F, Zucca E, Wilson WH. The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA. *Hematol Oncol*. 2019. 38:34-37.

332. Howe MK, Dowdell K, Roy A, Niemela JE, Wilson W, McElwee JJ, Hughes JD, Cohen JI. Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase. *Front Immunol* 2019.
333. Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci Immunol*. 2020 Jun 5;5(48).
334. Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. *Cancer J*. 2020 May/Jun;26(3):195-205.
335. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. *J Clin Oncol*. 2020. 38:2519-2529.
336. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. *Cancer Cell*. 2020. 37:551-568.
337. Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. *Blood*. 2020 135:2224-2234.
338. Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. *J Clin Oncol*. 2020. 38:1527-1538.
339. Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. *Blood*. 2020. 135:1344-1352.
340. Pittaluga S, Nicolae A, Wright GW, Melani C, Roschewski M, Steinberg S, Huang D, Staudt LM, Jaffe ES, Wilson WH. Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. *Blood Cancer Discov* 2020; 1:1-7.

341. Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. *Cancer J* 2020, 26:195-205.
342. Roschewski M, Wilson WH. Expanding the Precision Medicine Toolkit with circulating Tumor DNA. *JCO Oncol Pract.* 2020 16:569-570.
343. de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH. Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. *Leuk Lymphoma* 2021. 62:810-818.
344. Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas AN, Jacob AP, Yusko E, Jaffe ES, Wilson WH, Roschewski MJ. Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL. *Blood Adv.* 2021. 5:4198-4210.
345. Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. *Nat Biotechnol.* 2021. 39:1537-1547.
346. Balasubramanian S, Wang S, Major C, Hodgkinson B, Schaffer M, Sehn LH, Johnson P, Zinzani PL, Carey J, Shreeve SM, Sun S, Gerecitano J, Vermeulen J, Staudt LM, Wilson W. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. *Br J Haematol.* 2021. 194:83-91.
347. Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, Alizadeh AA. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. *J Clin Oncol.* 2021. 39:2605-2616.
348. Wilson WH, Phillips T, Popplewell L, de Vos S, Chhabra S, Kimball AS, Beaupre D, Huang DW, Wright G, Kwei K, Ping J, Neuenburg JK, Staudt LM. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2021. 62:2094-2106.

349. Wilson WH, Wright G, Huang DW, Hodgkinson B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M, and Staudt LM. Effect of Ibrutinib with R-CHOP Chemotherapy in Genetic Subtypes of DLBCL. *Cancer Cell* 2021, 39:1643-1653.
350. Soleimani A, Navarro A, Liu D.....Wilson WH, Wiestner A and Saba NS. CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. *Leuk Lymphoma*. 2022. 63:911-917.
351. Shaffer AL, Phelan JD, Wang JQ,Wilson WH, Wiestner A and Staudt LM. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. *Blood Cancer Discovery* 2021. 2:630-647.
352. Roschewski M, Longo DL, Wilson WH. CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How? *N Engl J Med* 2022. 386:692-696.
353. Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Saba N, Lindenberg L, Mena E, Bergvall E, Lucas AN, Jacob A, Yusko E, Steinberg SM, Jaffe ES, Wiestner A, Wilson WH, Roschewski M. Circulating Tumor DNA Predicts Therapeutic Outcome in Mantle Cell Lymphoma. *Blood Advances*. 2022. 6:2667-2680.
354. Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating Tumor DNA in Lymphoma: Principles and Future Directions. *Blood Cancer Discovery* 2022. 3:5-15.
355. Melani C, Wilson WH. Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure. *Leukemia and Lymphoma*. 2022. 63:511-513.
356. Soleimani A, Navarro A, Liu D, Herman SEM, Chuang SS, Slavutsky I, Narbaitz M, Safah H, Schmiegl J, Lefante J, Roschewski M, Wilson WH, Wiestner A, Saba NS. *Leukemia and Lymphoma*. 2022. 63:911-917.
357. Obiorah IE, Wang HW, Ma D, Martin W, Wilson WH, Braylan R. The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow. *Am J of Clin Path*. 2022. 157:709-717.
358. Radtke AJ, Postovalova E, Varlamova A..... Wilson WH, Jaffe ES, Staudt LM, Roschewski M, Germain RN. A Multi-scale, Multiomic Atlas of Human Normal and Follicular Lymphoma Lymph Nodes. bioRxiv (Cold Spring Harbor Lab). 2022.
359. Campo E, Jaffe ES, Cook JR..... Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood*. 2022. 140:1229-1253.

360. Roschewski M, Staudt LM, Wilson WH. Burkitt Lymphoma. *N Eng J Med*. 2022. 387:1111-1122.
361. Zhu J, Hong X, Song YQ.....Wilson W, Vermeulen J. Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. *ejHaem*. 2022. 3:1154-1164.
362. Leval LD, Alizadeh AA, Bergsagel PL..... Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW. Genomic profiling for clinical decision making in lymphoid neoplasms. *Blood*. 2022. 140:2193-2227.
363. Thomas N, Dreval K, Gerhard DS..... Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. *blood*. 2023. 141:904-916.
364. Lai C, Cole DE, Steinberg SM, Lucas N, Dombi E, Melani C, Roschewski M, Balis F, Widemann BC, Wilson WH. *blood advances*. 2023. 7:529-532.
365. Torka P, Pederson LD, Knopp MV..... Wilson WH, Leonard JP, Bartlett NL, Schöder H, Ruppert AS. Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis. *Cancer Medicine*. 2023. 12:8211-8217.
366. Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song JY, Calattini S, Kawada JI, Price DA, Chattopadhyay PK, Roederer M, Lucas AN, Steinberg SM, Jaffe ES, Cohen JI, Wilson WH. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. *Lancet Haematology*. 2023. 10:346-358.
367. Johnson PWM, Balasubramanian S, Hodgkinson B, Shreeve SM, Sun S, Srinivasan S, Steele AJ, Vermeulen J, Sehn LH, Wilson WH. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. *blood advances*. 2023. 7:2008-2017.
368. Lakhotia R, Dunleavy K, Abramson JS, Link BK, Powell BL, Melani C, Lucas AN, Steinberg SM, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Noy A, Wilson WH, Roschewski M. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R. *blood advances*. 2023. 7:5320-5324.
369. Melani C, Lakhotia R, Pittaluga S.....Roschewski M, LM Staudt, Wilson WH. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. *N Eng J Med*. 2024. 390:2143-2155.

Bibliography Statistics:

Google Scholar

Citations	All: 80429	Since 2020: 25611
h-index	All: 117	Since 2020: 69
i10-index	All: 361	Since 2020: 214